nach oben

Erschienen in:

01.05.2014 | Laboratory Investigation

Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro

verfasst von: Xiaosi Han, Rong Li, Wenbin Zhang, Xiuhua Yang, Crystal G. Wheeler, Gregory K. Friedman, Paula Province, Qiang Ding, Zhiying You, Hassan M. Fathallah-Shaykh, G. Yancey Gillespie, Xinyang Zhao, Peter H. King, L. Burt Nabors

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Protein arginine methyltransferase 5 (PRMT5) catalyzes the formation of ω-NG,N′G-symmetric dimethylarginine residues on histones as well as other proteins. These modifications play an important role in cell differentiation and tumor cell growth. However, the role of PRMT5 in human glioma cells has not been characterized. In this study, we assessed protein expression profiles of PRMT5 in control brain, WHO grade II astrocytomas, anaplastic astrocytomas, and glioblastoma multiforme (GBM) by immunohistochemistry. PRMT5 was low in glial cells in control brain tissues and low grade astrocytomas. Its expression increased in parallel with malignant progression, and was highly expressed in GBM. Knockdown of PRMT5 by small hairpin RNA caused alterations of p-ERK1/2 and significantly repressed the clonogenic potential and viability of glioma cells. These findings indicate that PRMT5 is a marker of malignant progression in glioma tumors and plays a pivotal role in tumor growth.

Yang Y, Bedford MT (2013) Protein arginine methyltransferases and cancer. Nat Rev 13(1):37–50CrossRef

Friesen WJ, Paushkin S, Wyce A et al (2001) The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Mol Cell Biol 21(24):8289–8300PubMedCentralPubMedCrossRef

Hsu JM, Chen CT, Chou CK et al (2011) Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol 13(2):174–181PubMedCentralPubMedCrossRef

Jansson M, Durant ST, Cho EC et al (2008) Arginine methylation regulates the p53 response. Nat Cell Biol 10(12):1431–1439PubMedCrossRef

Teng Y, Girvan AC, Casson LK et al (2007) AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res 67(21):10491–10500PubMedCrossRef

Scoumanne A, Zhang J, Chen X (2009) PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res 37(15):4965–4976PubMedCentralPubMedCrossRef

Andreu-Perez P, Esteve-Puig R, Esteve-Puig R, de Torre-Minguela C et al (2011) Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 4(190):ra58PubMedCrossRef

Pal S, Baiocchi RA, Byrd JC et al (2007) Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J 26(15):3558–3569PubMedCentralPubMedCrossRef

Wang L, Pal S, Sif S (2008) Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol 28(20):6262–6277PubMedCentralPubMedCrossRef

10.

Kim JM, Sohn HY, Yoon SY et al (2005) Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 11(2 Pt 1):473–482PubMed

11.

Eckert D, Biermann K, Nettersheim D et al (2008) Expression of BLIMP1/PRMT5 and concurrent histone H2A/H4 arginine 3 dimethylation in fetal germ cells, CIS/IGCNU and germ cell tumors. BMC Dev Biol 8:106PubMedCentralPubMedCrossRef

12.

Powers MA, Fay MM, Factor RE et al (2011) Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res 71(16):5579–5587PubMedCentralPubMedCrossRef

13.

Bao X, Zhao S, Liu T et al (2013) Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem 61(3):206–217PubMedCentralPubMedCrossRef

14.

Tanaka H, Hoshikawa Y, Oh-hara T et al (2009) PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res 7(4):557–569PubMedCrossRef

15.

Yang M, Sun J, Sun X et al (2009) Caenorhabditis elegans protein arginine methyltransferase PRMT-5 negatively regulates DNA damage-induced apoptosis. PLoS Genet 5(6):e1000514PubMedCentralPubMedCrossRef

16.

Aggarwal P, Vaites LP, Kim JK et al (2010) Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18(4):329–340PubMedCentralPubMedCrossRef

17.

Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S (2004) Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 24(21):9630–9645PubMedCentralPubMedCrossRef

18.

Tee WW, Pardo M, Theunissen TW et al (2010) PRMT5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev 24(24):2772–2777PubMedCentralPubMedCrossRef

19.

Chittka A (2010) Dynamic distribution of histone H4 arginine 3 methylation marks in the developing murine cortex. PLoS One 5(11):e13807PubMedCentralPubMedCrossRef

20.

Chittka A, Nitarska J, Grazini U, Richardson WD (2012) Transcription factor positive regulatory domain 4 (PRDM4) recruits protein arginine methyltransferase 5 (PRMT5) to mediate histone arginine methylation and control neural stem cell proliferation and differentiation. J Biol Chem 287(51):42995–43006PubMedCentralPubMedCrossRef

21.

Jemal A, Murray T, Samuels A et al (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1):5–26PubMedCrossRef

22.

Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489PubMed

23.

Tran B, Rosenthal MA (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 17(4):417–421PubMedCrossRef

24.

Ishibashi H, Suzuki T, Suzuki S et al (2003) Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 88(5):2309–2317PubMedCrossRef

25.

Robertson D, Savage K, Reis-Filho JS, Isacke CM (2008) Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol 9:13PubMedCentralPubMedCrossRef

26.

Inai T, Mancuso M, Hashizume H et al (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165(1):35–52PubMedCentralPubMedCrossRef

27.

Wiederschain D, Wee S, Chen L et al (2009) Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8(3):498–504PubMedCrossRef

28.

Han X, Stewart JE Jr, Bellis SL et al (2001) TGF-beta1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate. Oncogene 20(55):7976–7986PubMedCrossRef

29.

Karkhanis V, Hu YJ, Baiocchi RA et al (2011) Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci 36(12):633–641PubMedCentralPubMedCrossRef

30.

Lee JH, Cook JR, Yang ZH et al (2005) PRMT7, a new protein arginine methyltransferase that synthesizes symmetric dimethylarginine. J Biol Chem 280(5):3656–3664PubMedCrossRef

31.

Zhao Q, Rank G, Tan YT et al (2009) PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 16(3):304–311PubMedCrossRef

32.

Ancelin K, Lange UC, Hajkova P et al (2006) Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat Cell Biol 8(6):623–630PubMedCrossRef

33.

Bedford MT, Clarke SG (2009) Protein arginine methylation in mammals: who, what, and why. Mol Cell 33(1):1–13PubMedCentralPubMedCrossRef

34.

Huang J, Vogel G, Yu Z, Almazan G, Richard S (2011) Type II arginine methyltransferase PRMT5 regulates gene expression of inhibitors of differentiation/DNA binding Id2 and Id4 during glial cell differentiation. J Biol Chem 286(52):44424–44432PubMedCentralPubMedCrossRef

35.

Friedmann-Morvinski D, Bushong EA, Ke E et al (2012) Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338(6110):1080–1084PubMedCentralPubMedCrossRef

36.

Dunn GP, Rinne ML, Wykosky J et al (2012) Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 26(8):756–784PubMedCentralPubMedCrossRef

37.

Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110PubMedCentralPubMedCrossRef

38.

Krakstad C, Chekenya M (2010) Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9:135PubMedCentralPubMedCrossRef

39.

Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80(2):179–185PubMedCrossRef

40.

Olsen BB, Svenstrup TH, Guerra B (2012) Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells. Int J Oncol 41(6):1967–1976PubMedCentralPubMed

41.

Pang L, Sawada T, Decker SJ, Saltiel AR (1995) Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 270(23):13585–13588PubMedCrossRef

42.

Ravi RK, Weber E, McMahon M et al (1998) Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Investig 101(1):153–159PubMedCentralPubMedCrossRef

43.

Cho EC, Zheng S, Munro S et al (2012) Arginine methylation controls growth regulation by E2F-1. EMBO J 31(7):1785–1797PubMedCentralPubMedCrossRef

Titel: Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro
verfasst von: Xiaosi Han
Rong Li
Wenbin Zhang
Xiuhua Yang
Crystal G. Wheeler
Gregory K. Friedman
Paula Province
Qiang Ding
Zhiying You
Hassan M. Fathallah-Shaykh
G. Yancey Gillespie
Xinyang Zhao
Peter H. King
L. Burt Nabors
Publikationsdatum: 01.05.2014
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1419-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Heat shock protein 47 regulated by miR-29a to enhance glioma tumor growth and invasion

Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases

Prognostic paradox: brain damage around the glioblastoma resection cavity

A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent